Codexis to Participate in TD Cowen 46th Annual Health Care Conference
Rhea-AI Summary
Codexis (NASDAQ: CDXS) will attend the TD Cowen 46th Annual Health Care Conference in Boston March 2-4, 2026. Management will join a fireside chat on March 3, 2026 at 11:50 am ET. A live webcast will be available on the company's Investor Relations site and replayed for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – CDXS
In the Feb 17 session, CDXS gained 0.83%, reflecting a mild positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Quality certification | Positive | -3.1% | ISO 9001:2015 certification for HQ, R&D labs, and non-GMP manufacturing. |
| Jan 07 | Platform evaluation deal | Positive | -1.2% | Axolabs evaluation agreement for ECO Synthesis oligonucleotide platform. |
| Nov 10 | GMP facility lease | Positive | +3.5% | Lease of 34,000 sq ft GMP site to expand internal production. |
| Nov 06 | Earnings and restructuring | Negative | -5.3% | Q3 2025 results with revenue decline, layoffs, and cost actions. |
| Oct 29 | Platform evaluation deal | Positive | -6.6% | Nitto Denko Avecia evaluation of ECO Synthesis for siRNA manufacturing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent partnership and certification news often saw negative next-day reactions, while capacity expansion and a weaker earnings print aligned with their respective price moves.
Over the last several months, Codexis announced quality and capacity milestones and new platform evaluations. Highlights include ISO 9001:2015 certification on Feb 10, 2026, multiple ECO Synthesis® evaluation agreements with Axolabs and Nitto Denko Avecia, and a lease for a 34,000 sq ft GMP facility announced on Nov 10, 2025. The Q3 2025 earnings on Nov 6, 2025 detailed restructuring and a cash runway extension. Today’s conference participation fits into this ongoing effort to showcase the ECO Synthesis platform and broader capabilities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the TD Cowen 46th Annual Health Care Conference, being held March 2-4, 2026, in Boston, Massachusetts.
Management will participate in a fireside chat on Tuesday, March 3, 2026, at 11:50 am ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, https://ir.codexis.com. A replay will be archived for 90 days following the event.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis® manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Georgia Erbez
(650) 421-8100
ir@codexis.com
